Eidos Therapeutics Inc (NASDAQ:EIDX) Expected to Earn FY2019 Earnings of ($1.03) Per Share

Share on StockTwits

Eidos Therapeutics Inc (NASDAQ:EIDX) – Analysts at Svb Leerink cut their FY2019 earnings per share estimates for Eidos Therapeutics in a research note issued on Thursday, December 5th. Svb Leerink analyst M. Foroohar now expects that the company will post earnings per share of ($1.03) for the year, down from their prior estimate of ($1.02). Svb Leerink also issued estimates for Eidos Therapeutics’ Q4 2019 earnings at ($0.51) EPS, Q1 2020 earnings at ($0.60) EPS, Q2 2020 earnings at ($0.62) EPS, Q3 2020 earnings at ($0.77) EPS, Q4 2020 earnings at ($0.81) EPS and FY2020 earnings at ($2.79) EPS.

Several other research analysts also recently issued reports on EIDX. Piper Jaffray Companies upped their price objective on Eidos Therapeutics from $55.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Zacks Investment Research raised Eidos Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a report on Monday, November 18th. Roth Capital increased their price target on Eidos Therapeutics from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, November 1st. ValuEngine downgraded Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Barclays downgraded Eidos Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $37.00 to $45.00 in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $52.00.

NASDAQ:EIDX opened at $60.15 on Monday. The stock’s fifty day moving average price is $50.04 and its two-hundred day moving average price is $39.77. Eidos Therapeutics has a 52-week low of $11.15 and a 52-week high of $61.94. The company has a debt-to-equity ratio of 0.03, a quick ratio of 17.00 and a current ratio of 17.00. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -32.34 and a beta of -0.87.

Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.48. The firm had revenue of $26.69 million for the quarter.

Several hedge funds have recently bought and sold shares of EIDX. Bank of Montreal Can lifted its stake in shares of Eidos Therapeutics by 151.8% in the 2nd quarter. Bank of Montreal Can now owns 1,385 shares of the company’s stock valued at $43,000 after purchasing an additional 835 shares during the period. SG Americas Securities LLC bought a new stake in shares of Eidos Therapeutics in the 2nd quarter valued at $125,000. Metropolitan Life Insurance Co NY bought a new stake in shares of Eidos Therapeutics in the 1st quarter valued at $143,000. Strs Ohio increased its position in shares of Eidos Therapeutics by 457.1% in the 2nd quarter. Strs Ohio now owns 11,700 shares of the company’s stock valued at $363,000 after buying an additional 9,600 shares in the last quarter. Finally, Swiss National Bank bought a new stake in shares of Eidos Therapeutics in the 2nd quarter valued at $426,000. 30.46% of the stock is currently owned by institutional investors.

In other news, insider Jonathan C. Fox sold 15,000 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $55.25, for a total value of $828,750.00. Also, CFO Christine Siu sold 20,000 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $59.75, for a total value of $1,195,000.00. In the last three months, insiders sold 112,500 shares of company stock worth $6,273,275. 70.10% of the stock is currently owned by company insiders.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Featured Article: How Buying a Call Option Works

Earnings History and Estimates for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Netflix  Receives Media Impact Score of 0.36
Netflix Receives Media Impact Score of 0.36
New Energy Systems Group.  Receives News Impact Score of -5.00
New Energy Systems Group. Receives News Impact Score of -5.00
Boeing  Earning Extremely Critical Press Coverage, Analysis Shows
Boeing Earning Extremely Critical Press Coverage, Analysis Shows
Borr Drilling Limited’s  Lock-Up Period To Expire  on January 27th
Borr Drilling Limited’s Lock-Up Period To Expire on January 27th
Invesco CEF Income Composite ETF  Sets New 12-Month High After Dividend Announcement
Invesco CEF Income Composite ETF Sets New 12-Month High After Dividend Announcement
MSC Industrial Direct  Stock Price Down 7.4% on Insider Selling
MSC Industrial Direct Stock Price Down 7.4% on Insider Selling


© 2006-2020 Ticker Report